Human papillomavirus (HPV) remains one of the leading causes of preventable cancers, including cervical cancer. However, even though we have effective mechanisms to prevent cervical cancer—such as the WHO global strategy to eliminate it—this disease still remains a public health challenge.

The 90–70–90 targets for 2030 have been endorsed: 90% of girls fully vaccinated against HPV by age 15; 70% of women screened with a high-performance test (at ages 35 and 45); and 90% of women with pre-cancer and 90% of women with invasive cancer receiving timely treatment.

ITPC EECA and the Eurasian Community for Access to Treatment (ECAT) reaffirm their commitment to the 90–70–90 targets and view access to cervical cancer prevention and treatment as a matter of human rights and health-system sustainability across the EECA region.

Since 2025, we have been working to analyze the market for HPV prevention vaccines and medicines used in cervical cancer treatment in order to identify key access barriers and outline practical steps to address them. These barriers include high prices and patent monopolies, as well as the need for product registration and inclusion in national immunization and oncology care programs.

As part of this work, we have already assessed the patent status of a number of vaccines and medicines in several EECA countries. In 2026, together with colleagues from Belarus, Kyrgyzstan, Kazakhstan, and Uzbekistan, we plan to continue this effort and move toward systematic monitoring covering prices, procurement volumes, registration status, and other key parameters that determine real-world access to prevention and treatment.

We also plan to engage in dialogue with vaccine and medicine manufacturers through ECAT. Meetings and consultations are already scheduled for 2026 to discuss access conditions, barriers, and regional solutions. This dialogue builds on prior engagement by community representatives in global initiatives, such as World CAB 2025.

We believe the 90–70–90 target is achievable for the EECA region, and we have tools that work: vaccination, effective screening, and treatment. Our task is to ensure that these tools are accessible to everyone who needs them across EECA countries.